Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
5.28
-0.07 (-1.31%)
At close: Jun 18, 2026, 4:00 PM EDT
5.36
+0.08 (1.52%)
After-hours: Jun 18, 2026, 6:54 PM EDT
Aligos Therapeutics Revenue
Aligos Therapeutics had revenue of $2.83M in the quarter ending March 31, 2026, with 809.97% growth. This brings the company's revenue in the last twelve months to $4.71M, up 43.88% year-over-year. In the year 2025, Aligos Therapeutics had annual revenue of $2.19M, down -44.59%.
Revenue (ttm)
$4.71M
Revenue Growth
+43.88%
P/S Ratio
6.94
Revenue / Employee
$57,378
Employees
82
Market Cap
32.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.19M | -1.76M | -44.59% |
| Dec 31, 2024 | 3.95M | -11.58M | -74.60% |
| Dec 31, 2023 | 15.53M | 1.62M | 11.66% |
| Dec 31, 2022 | 13.91M | 9.55M | 219.04% |
| Dec 31, 2021 | 4.36M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nutriband | 1.80M |
| Daré Bioscience | 1.16M |
| ABVC BioPharma | 797.92K |
| Lisata Therapeutics | 170.00K |
| Serina Therapeutics | 130.00K |
| Actinium Pharmaceuticals | 90.00K |
| Senti Biosciences Holdings | 38.00K |
ALGS News
- 23 days ago - Aligos Therapeutics initiated with a Buy at Lake Street - TheFly
- 24 days ago - Aligos Therapeutics presents data at EASL congress - TheFly
- 24 days ago - Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - GlobeNewsWire
- 4 weeks ago - Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 4 weeks ago - Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 5 weeks ago - Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics Earnings release: Q1 2026 - Filings